These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 15591619)

  • 1. High-avidity CD8+ T cells: optimal soldiers in the war against viruses and tumors.
    Alexander-Miller MA
    Immunol Res; 2005; 31(1):13-24. PubMed ID: 15591619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular mechanisms and biological significance of CTL avidity.
    Snyder JT; Alexander-Miller MA; Berzofskyl JA; Belyakov IM
    Curr HIV Res; 2003 Jul; 1(3):287-94. PubMed ID: 15046253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High Peptide Dose Vaccination Promotes the Early Selection of Tumor Antigen-Specific CD8 T-Cells of Enhanced Functional Competence.
    Carretero-Iglesia L; Couturaud B; Baumgaertner P; Schmidt J; Maby-El Hajjami H; Speiser DE; Hebeisen M; Rufer N
    Front Immunol; 2019; 10():3016. PubMed ID: 31969886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apoptosis-regulated low-avidity cancer-specific CD8(+) T cells can be rescued to eliminate HER2/neu-expressing tumors by costimulatory agonists in tolerized mice.
    Black CM; Armstrong TD; Jaffee EM
    Cancer Immunol Res; 2014 Apr; 2(4):307-19. PubMed ID: 24764578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytomegalovirus immune evasion sets the functional avidity threshold for protection by CD8 T cells.
    Hamdan S; Reddehase MJ; Holtappels R
    Med Microbiol Immunol; 2023 Apr; 212(2):153-163. PubMed ID: 35364731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The avidity of cross-reactive virus-specific T cells for their viral and allogeneic epitopes is variable and depends on epitope expression.
    van den Heuvel H; Heutinck KM; van der Meer-Prins EMW; Franke-van Dijk MEI; van Miert PPMC; Zhang X; Ten Berge IJM; Claas FHJ
    Hum Immunol; 2018 Jan; 79(1):39-50. PubMed ID: 29100943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-4 and IL-13 mediated down-regulation of CD8 expression levels can dampen anti-viral CD8⁺ T cell avidity following HIV-1 recombinant pox viral vaccination.
    Wijesundara DK; Jackson RJ; Tscharke DC; Ranasinghe C
    Vaccine; 2013 Sep; 31(41):4548-55. PubMed ID: 23933364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human CD8+ T-regulatory cells with low-avidity T-cell receptor specific for minor histocompatibility antigens.
    Burlingham WJ; Goulmy E
    Hum Immunol; 2008 Nov; 69(11):728-31. PubMed ID: 18812197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [MHC tetramers: tracking specific immunity].
    Kosor E; Gagro A; Drazenović V; Kuzman I; Jeren T; Rakusić S; Rabatić S; Markotić A; Gotovac K; Sabioncello A; Cecuk E; Kerhin-Brkljacić V; Gjenero-Margan I; Kaić B; Mlinarić-Galinović G; Kastelan A; Dekaris D
    Acta Med Croatica; 2003; 57(4):255-9. PubMed ID: 14639858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in functional but not structural avidity during differentiation of CD8+ effector cells in vivo after virus infection.
    Amoah S; Yammani RD; Grayson JM; Alexander-Miller MA
    J Immunol; 2012 Jul; 189(2):638-45. PubMed ID: 22706075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes to peptide structure, not concentration, contribute to expansion of the lowest avidity cytotoxic T lymphocytes.
    Leggatt GR; Narayan S; Fernando GJ; Frazer IH
    J Leukoc Biol; 2004 Oct; 76(4):787-95. PubMed ID: 15240746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cutting edge: CD8+ T cell clones possess the potential to differentiate into both high- and low-avidity effector cells.
    Kroger CJ; Alexander-Miller MA
    J Immunol; 2007 Jul; 179(2):748-51. PubMed ID: 17617563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-dressed dendritic cells drive memory CD8+ T-cell activation after viral infection.
    Wakim LM; Bevan MJ
    Nature; 2011 Mar; 471(7340):629-32. PubMed ID: 21455179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flow cytometry-based TCR-ligand Koff -rate assay for fast avidity screening of even very small antigen-specific T cell populations ex vivo.
    Nauerth M; Stemberger C; Mohr F; Weißbrich B; Schiemann M; Germeroth L; Busch DH
    Cytometry A; 2016 Sep; 89(9):816-25. PubMed ID: 27564267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased Protein Degradation Improves Influenza Virus Nucleoprotein-Specific CD8+ T Cell Activation In Vitro but Not in C57BL/6 Mice.
    Altenburg AF; van de Sandt CE; van Trierum SE; De Gruyter HLM; van Run PRWA; Fouchier RAM; Roose K; Saelens X; Volz A; Sutter G; de Vries RD; Rimmelzwaan GF
    J Virol; 2016 Nov; 90(22):10209-10219. PubMed ID: 27581985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Essential Role of the Avidity of T-Cell Receptor in Differentiation of Self-Antigen-reactive CD8+ T Cells.
    Kondo K; Fujiki F; Nakajima H; Yatsukawa E; Morimoto S; Tatsumi N; Nishida S; Nakata J; Oka Y; Tsuboi A; Hosen N; Oji Y; Sugiyama H
    J Immunother; 2016 Apr; 39(3):127-39. PubMed ID: 26938946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of CTL function among high-avidity tumor-specific CD8+ T cells following tumor infiltration.
    Janicki CN; Jenkinson SR; Williams NA; Morgan DJ
    Cancer Res; 2008 Apr; 68(8):2993-3000. PubMed ID: 18413769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Avidity of CD8 T cells sharpens immunodominance.
    Dzutsev AH; Belyakov IM; Isakov DV; Margulies DH; Berzofsky JA
    Int Immunol; 2007 Apr; 19(4):497-507. PubMed ID: 17376783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increasing viral dose causes a reversal in CD8+ T cell immunodominance during primary influenza infection due to differences in antigen presentation, T cell avidity, and precursor numbers.
    Luciani F; Sanders MT; Oveissi S; Pang KC; Chen W
    J Immunol; 2013 Jan; 190(1):36-47. PubMed ID: 23233728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unique IL-13Rα2-based HIV-1 vaccine strategy to enhance mucosal immunity, CD8(+) T-cell avidity and protective immunity.
    Ranasinghe C; Trivedi S; Stambas J; Jackson RJ
    Mucosal Immunol; 2013 Nov; 6(6):1068-80. PubMed ID: 23403475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.